Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package

Centre Hospitalier Universitaire Dijon130 enrolled

Overview

The aim of this study is to analyze the relationship between the blood biomarker GDF-15 and heart damage after stroke. It is being conducted in France, in the Neurology Department of the Dijon University Hospital (Burgundy). The research is interventional because a biological blood test will be performed, as well as a heart rhythm recording and several cardiac echograms during the hospitalization of the participants and during the follow-up consultation scheduled 4 to 6 months after the stroke. A total of 130 stroke patients will participate in this study. Participation includes 4 visits: * Inclusion visit (within 24 hours of the first stroke symptoms) * visit 1 (within 24 to 72 hours of stroke) * visit 2 (within 48 hours of visit 1) * Visit 3 (approximately 4-6 months post-stroke)

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

130

Conditions

Ischemic Stroke

Interventions

Inclusion visit, V1, V2 and V3

transthoracic echocardiographyPROCEDURE

V1, V2 and V3

standard biologyBIOLOGICAL

Inclusion visit

determination of serum GDF-15, osteoprotegerin and ST-2BIOLOGICAL

Inclusion visit, V1, V2 and V3

Ultrasensitive Troponin-IcBIOLOGICAL

Inclusion visit, V1, V2 and V3

Collection of clinical and radiological dataOTHER

Inclusion visit, V1 and V3: clinical data only V2: clinical and radiological data

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult with acute symptomatic cerebral infarction documented by brain imaging on admission (cerebral angioscan or cerebral MRI) * Whose first symptoms appeared within 24 hours before inclusion * Whose consent to participate in this study was obtained from the patient or a close relative. Exclusion Criteria: * Person with a history of symptomatic stroke, either ischemic or hemorrhagic * Anyone with a history of heart disease including: atrial fibrillation or flutter (known or discovered on admission), chronic heart failure, pacemaker, defibrillator, or other cardiac devices * Person with acute heart failure, suspected infective endocarditis, STEMI, or concurrent pulmonary embolism * A person who is not a member or beneficiary of a social security system * Person deprived of liberty * Person subject to a legal protection measure (curatorship, guardianship) * Person subject to a legal protection measure * Pregnant, parturient or breastfeeding woman

Locations (1)

Chu Dijon Bourgogne

Dijon, France

RECRUITING

Outcomes

Primary Outcomes

Global Longitudinal Strain (GLS) of the left ventricle measured by trans-thoracic ultrasound (TTE)

Time frame: within 24 to 72 hours post-stroke

Central Contacts

Yannick BEJOT

CONTACT

0380293753 yannick.bejot@chu-dijon.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.